drugset / Trial / NCT00884663
Candesartan Versus Propranolol for Migraine Prevention
Phase 2/3
Completed
72 enrolled
Norwegian University of Science and Technology
AstraZeneca · collabKragerø Tablettproduksjon as, Norway · collabSt. Olavs Hospital · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
The main aim of the present study is to compare candesartan with propranolol for migraine prophylaxis.
Timeline
- Start
- 2009-04
- Primary completion
- 2012-03
- Completion
- 2012-03
Outcome
Met primary endpoint
paper candesartan and propranolol were both superior to placebo: 2.95 (95% confidence interval: 2.35-3.55%) and 2.91 (2.36-3.45%), versus 3.53 (2.98-4.08%) for migraine days per month (p = 0.02 for both comparisons PMID 24335848 ↗
paper Candesartan was non-inferior to propranolol (and vice versa). PMID 24335848 ↗
Publications
- Background Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003 Jan 1;289(1):65-9. doi: 10.1001/jama.289.1.65.
- Results Stovner LJ, Linde M, Gravdahl GB, Tronvik E, Aamodt AH, Sand T, Hagen K. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014 Jun;34(7):523-32. doi: 10.1177/0333102413515348. Epub 2013 Dec 11.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Candesartan | Unknown | 16 mg | — |
| Comparator | Propranolol | Small molecule | 160 mg | — |